Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial updating the safety, tolerability, immunogenicity, and preliminary efficacy of ITI-1001 for newly diagnosed glioblastoma; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ITI-1001

Snippet

Sponsor: Immunomic Therapeutics, Inc. | Conditions: Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING